News
ASND
92.60
-0.39%
-0.36
Ascendis Pharma (NASDAQ:ASND) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Simply Wall St. · 06/16 15:42
Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for TransCon™ PTH to be a Replacement Therapy for Adult Hypoparathyroidism at ENDO 2022
– Late-breaker oral presentation of TransCon PTH Phase 3 PaTHway Trial data in adult hypoparathyroidism on Tuesday, June 14 – Oral presentation of TransCon PTH Phase 2 PaTH Forward Trial Open-Label Extension Data in adult hypoparathyroidism on Monday, June...
GlobeNewswire · 06/07 12:00
Ascendis Pharma Reports Results From Co. Investment, VISEN Pharma's Phase 3 Trial Of TransCon In China, Results Consistent With Ascendis Pharma's Trial
   VISEN’s Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patients treated with TransCon™ hGH demonstrated greater annualized height velocity at 52-weeks
Benzinga · 05/23 12:10
Ascendis Pharma A/S Announces New Commercial Endocrinology Leadership Appointments
- Joe Kelly has been appointed to the newly created role of Head of U.S. Commercial, Endocrinology - Scott A. Holmes has been appointed to the newly created role of Head of Global Commercial Strategy, Endocrinology - Jesper Høiland, Global Chief Commercial...
GlobeNewswire · 05/23 12:00
Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial
- VISEN’s Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patients treated with TransCon™ hGH demonstrated greater annualized height velocity at 52-weeks (p=0.0010) compared to patients treated with daily growth hormone -...
GlobeNewswire · 05/23 12:00
Ascendis, Visen' TransCon hGH meets main goal in growth hormone deficiency China trial in children
Ascendis Pharma (ASND) and Visen Pharmaceuticals' lonapegsomatropin (TransCon hGH) showed to be better than a daily human growth hormone (hGH) in a phase 3 trial in children with growth hormone deficiency (GHD)
Seekingalpha · 05/23 09:20
--Berenberg Bank Adjusts Ascendis Pharma's Price Target to $168 From $192, Maintains Buy Rating
MT Newswires · 05/16 07:26
What 14 Analyst Ratings Have To Say About Ascendis Pharma
Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings:
Benzinga · 05/12 21:06
Ascendis Pharma stock falls as 5 firms cut price target after Q1 results
Ascendis Pharma (ASND) stock fell ~5% on May 12 after five firms lowered their price target on the stock following Q1 results. Wells Fargo cut its price target on ASND to
Seekingalpha · 05/12 17:30
Ascendis Pharma slides after Street analysts cut price target over SKYTROFA revenue miss
Ascendis Pharma (ASND -4.2%) fell sharply likely in reaction to Dovish biotech's earnings report that got the Wall Street's analysts off the ground to lower their price target over SKYTROFA cautious outlook. 
Seekingalpha · 05/12 17:21
Sector Update: Health Care Stocks Close Higher on Thursday
MT Newswires · 05/12 16:18
Cullinan Oncology, Concert Pharmaceuticals top healthcare gainers; Eargo, Senseonics lead losers' pack
Gainers: Cullinan Oncology (CGEM) +21%. Concert Pharmaceuticals (CNCE) +20%. Babylon Holdings (BBLN) +16%. Blue Water Vaccines (BWV) +14%.  ViewRay (VRAY) +10%. Losers: Eargo (EAR) -24%. Senseonics (SENS) -14%. Ascendis Pharma (ASND) -11%. Evaxion Biotech ...
Seekingalpha · 05/12 14:00
Sector Update: Health Care
MT Newswires · 05/12 13:51
Ascendis Slammed After Growth Hormone Drug Faces An Unexpected Challenge
Biotech stock Ascendis Pharma plummeted Thursday after its growth hormone deficiency treatment, Skytrofa, missed sales estimates.
Investor's Business Daily · 05/12 13:48
--Credit Suisse Adjusts Ascendis Pharma's Price Target to $123 from $194, Keeps Outperform Rating
MT Newswires · 05/12 10:59
--Oppenheimer Adjusts Ascendis Pharma Price Target to $154 From $166, Maintains Outperform Rating
MT Newswires · 05/12 10:48
--Wedbush Adjusts Ascendis Pharma's Price Target to $127 From $163, Keeps Outperform Rating
MT Newswires · 05/12 09:42
--SVB Securities Adjusts Ascendis Pharma's Price Target to $174 from $193, Keeps Outperform Rating
MT Newswires · 05/12 08:52
--Wells Fargo Adjusts Ascendis Pharma's Price Target to $176 From $190, Reiterates Overweight Rating
MT Newswires · 05/12 08:04
--Citigroup Adjusts Ascendis Pharma's Price Target to $158 From $187, Reiterates Buy Rating
MT Newswires · 05/12 07:59
More
Webull provides a variety of real-time ASND stock news. You can receive the latest news about Ascendis Pharma through multiple platforms. This information may help you make smarter investment decisions.
About ASND
ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, which is involved in manufacture products for rare diseases. The Company utilizes its TransCon technologies for treatment, which can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs. The Company is headquartered in Copenhagen, Denmark with offices in Heidelberg, Germany and Palo Alto, California.